$2.68T
Total marketcap
$44.33B
Total volume
BTC 49.83%     ETH 17.16%
Dominance

Hard to Treat Diseases HTDS Stock

0 USD {{ price }} 0.000000% {{change_pct}}%
Market Cap
5.48K USD
LOW - HIGH [24H]
0.0000 - 0.0000 USD
VOLUME [24H]
4.3K USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD

Hard to Treat Diseases Price Chart

Hard to Treat Diseases HTDS Financial and Trading Overview

Hard to Treat Diseases stock price 0.0000 USD
Previous Close 1.0E-5 USD
Open 1.0E-5 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 1.0E-5 - 1.0E-5 USD
52 Week Range 1.0E-5 - 1.0E-5 USD
Volume 5K USD
Avg. Volume 79 USD
Market Cap 54.82K USD
Beta (5Y Monthly) 9.083802
PE Ratio (TTM) Infinity
EPS (TTM) 0 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

HTDS Valuation Measures

Enterprise Value 306.74K USD
Trailing P/E Infinity
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 0.008901644
Price/Book (mrq) N/A
Enterprise Value/Revenue 0.05
Enterprise Value/EBITDA 0.299

Trading Information

Hard to Treat Diseases Stock Price History

Beta (5Y Monthly) 9.083802
52-Week Change 0%
S&P500 52-Week Change 20.43%
52 Week High 1.0E-5 USD
52 Week Low 1.0E-5 USD
50-Day Moving Average 1.0E-5 USD
200-Day Moving Average 1.0E-5 USD

HTDS Share Statistics

Avg. Volume (3 month) 79 USD
Avg. Daily Volume (10-Days) 500 USD
Shares Outstanding 5.48B
Float N/A
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 0.025%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2009
Most Recent Quarter (mrq) September 30, 2010
Next Fiscal Year End December 31, 2010

Profitability

Profit Margin 15.82%
Operating Margin (ttm) 15.94%
Gross Margin 28.94%
EBITDA Margin 16.64%

Management Effectiveness

Return on Assets (ttm) N/A
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 6.16M USD
Revenue Per Share (ttm) 0.001 USD
Quarterly Revenue Growth (yoy) 5.70%
Gross Profit (ttm) 1.42M USD
EBITDA 1.03M USD
Net Income Avi to Common (ttm) 974.3K USD
Diluted EPS (ttm) 0
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 202.9K USD
Total Cash Per Share (mrq) 0 USD
Total Debt (mrq) 450.45K USD
Total Debt/Equity (mrq) 20.63 USD
Current Ratio (mrq) 2.265
Book Value Per Share (mrq) 0

Cash Flow Statement

Operating Cash Flow (ttm) 1.03M USD
Levered Free Cash Flow (ttm) N/A

Profile of Hard to Treat Diseases

Country United States
State N/A
City Shenzhen
Address Room EF, 12F
ZIP 518040
Phone 86 755 8272 0498
Website https://www.mellowhope.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees N/A

Hard to Treat Diseases Inc. manufactures, supplies, and exports biopharmaceuticals and vaccines in China and internationally. The company offers biologicals, including reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection; chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection; and vaccines, which include rabies vaccine, ACYW135 meningococcal vaccine, influenza vaccine, Hepatitis A, and varicella vaccine. It markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East. Hard to Treat Diseases Inc. was founded in 2009 and is based in Shenzhen, China.

Q&A For Hard to Treat Diseases Stock

What is a current HTDS stock price?

Hard to Treat Diseases HTDS stock price today per share is 0.0000 USD.

How to purchase Hard to Treat Diseases stock?

You can buy HTDS shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Hard to Treat Diseases?

The stock symbol or ticker of Hard to Treat Diseases is HTDS.

Which industry does the Hard to Treat Diseases company belong to?

The Hard to Treat Diseases industry is Biotechnology.

How many shares does Hard to Treat Diseases have in circulation?

The max supply of Hard to Treat Diseases shares is 0.

What is Hard to Treat Diseases Price to Earnings Ratio (PE Ratio)?

Hard to Treat Diseases PE Ratio is now.

What was Hard to Treat Diseases earnings per share over the trailing 12 months (TTM)?

Hard to Treat Diseases EPS is 0 USD over the trailing 12 months.

Which sector does the Hard to Treat Diseases company belong to?

The Hard to Treat Diseases sector is Healthcare.